141 related articles for article (PubMed ID: 7625922)
1. Function of endocrine organs in hemodialyzed patients of long-term erythropoietin therapy.
Kokot F; Wiecek A; Schmidt-Gayk H; Marcinkowski W; Gilge U; Heidland A; Rudka R; Trembecki J
Artif Organs; 1995 May; 19(5):428-35. PubMed ID: 7625922
[TBL] [Abstract][Full Text] [Related]
2. Influence of long-term erythropoietin therapy on endocrine abnormalities in haemodialyzed patients.
Kokot F; Wiecek A; Schmidt-Gayk H; Marcinkowski W; Nieszporek T; Rudka R; Trembecki J
Przegl Lek; 1992; 49(1-2):43-9. PubMed ID: 1455006
[TBL] [Abstract][Full Text] [Related]
3. [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure].
Trembecki J; Kokot F; Wiecek A; Marcinkowski W; Rudka R
Pol Arch Med Wewn; 1995 Aug; 94(2):144-52. PubMed ID: 8596749
[TBL] [Abstract][Full Text] [Related]
4. [The effect of erythropoietin treatment on endocrine organ function in patients with terminal-stage kidney failure on hemodialysis].
Kokot F; Wiecek A; Grzeszczak W; Klin M; Klepacka J; Lao M
Ter Arkh; 1991; 63(6):86-9. PubMed ID: 1948756
[TBL] [Abstract][Full Text] [Related]
5. Influence of erythropoietin treatment on function of the pituitary-adrenal axis and somatotropin secretion in hemodialyzed patients.
Kokot F; Wiecek A; Grzeszczak W; Klin M
Clin Nephrol; 1990 May; 33(5):241-6. PubMed ID: 2162262
[TBL] [Abstract][Full Text] [Related]
6. [Does long-term human recombinant erythropoietin (rHuEPO) influence secretion of hormones regulating volume and pressure of arterial blood?].
Rudka R; Kokot F; Wiecek A; Marcinkowski W; Trembecki J
Pol Arch Med Wewn; 1994 Aug; 92(2):154-61. PubMed ID: 7800584
[TBL] [Abstract][Full Text] [Related]
7. Endocrine effects of erythropoietin.
Carlson HE; Graber ML; Gelato MC; Hershman JM
Int J Artif Organs; 1995 Jun; 18(6):309-14. PubMed ID: 8593965
[TBL] [Abstract][Full Text] [Related]
8. Influence of long-term erythropoietin treatment on insulin, glucagon, pancreatic polypeptide, and gastrin secretion in haemodialysed patients.
Kokot F; Nieszporek T; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Nephrol Dial Transplant; 1994; 9 Suppl 3():35-9. PubMed ID: 8072722
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients.
Charytan C; Goldfarb-Rumyantzev A; Wang YF; Schwenk MH; Spinowitz BS
Am J Nephrol; 1998; 18(6):498-503. PubMed ID: 9845824
[TBL] [Abstract][Full Text] [Related]
10. Influence of erythropoietin treatment on plasma renin activity, aldosterone, vasopressin and atrial natriuretic peptide in haemodialyzed patients.
Kokot F; Wiecek A; Grzeszczak W; Klin M
Miner Electrolyte Metab; 1990; 16(1):25-9. PubMed ID: 2139159
[TBL] [Abstract][Full Text] [Related]
11. [Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia].
Nieszporek T; Kokot F; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Pol Arch Med Wewn; 1995 Dec; 94(6):488-94. PubMed ID: 8618811
[TBL] [Abstract][Full Text] [Related]
12. Influence of erythropoietin treatment on follitropin and lutropin response to luliberin and plasma testosterone levels in haemodialyzed patients.
Kokot F; Wiecek A; Grzeszczak W; Klin M
Nephron; 1990; 56(2):126-9. PubMed ID: 2123018
[TBL] [Abstract][Full Text] [Related]
13. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy.
Caravaca F; Vagace JM; Aparicio A; Groiss J; Pizarro JL; Alonso N; Garcia MC; Arrobas M; Cubero J; Esparrago J
Am J Kidney Dis; 1992 Sep; 20(3):249-54. PubMed ID: 1519605
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis.
Hempenius LM; Van Dam PS; Marx JJ; Koppeschaar HP
J Endocrinol Invest; 1999 May; 22(5):369-76. PubMed ID: 10401711
[TBL] [Abstract][Full Text] [Related]
15. Influence of long term erythropoietin therapy on the hypothalamic-pituitary-thyroid axis in patients undergoing capd.
Tokgöz B; Utaş C; Doğukan A; Oymak O; Keleştimur F
Ren Fail; 2002 May; 24(3):315-23. PubMed ID: 12166698
[TBL] [Abstract][Full Text] [Related]
16. Endocrine abnormalities in patients with endstage renal failure.
Kokot F; Wiecek A; Grzeszczak W; Klepacka J; Klin M; Lao M
Adv Exp Med Biol; 1989; 260():61-7. PubMed ID: 2560346
[TBL] [Abstract][Full Text] [Related]
17. [Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure].
Nieszporek T; Kokot F; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
Przegl Lek; 1995; 52(12):590-3. PubMed ID: 8834657
[TBL] [Abstract][Full Text] [Related]
18. Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
Majdan M; Ksiazek A; Kozioł M; Spasiewicz D; Swatowski A; Solski J
Nephron; 1996; 73(3):425-9. PubMed ID: 8832602
[TBL] [Abstract][Full Text] [Related]
19. Oral iron absorption in hemodialysis patients treated with erythropoietin.
Donnelly SM; Posen GA; Ali MA
Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamo-hypophyseal thyroid and gonadal function before and after erythropoietin therapy in dialysis patients.
Ramirez G; Bittle PA; Sanders H; Bercu BB
J Clin Endocrinol Metab; 1992 Mar; 74(3):517-24. PubMed ID: 1740485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
